» Articles » PMID: 21217145

Conversion of ScFv Peptide-binding Specificity for Crystal Chaperone Development

Overview
Date 2011 Jan 11
PMID 21217145
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

In spite of advances in protein expression and purification over the last decade, many proteins remain recalcitrant to structure determination by X-ray crystallography. One emerging tactic to obtain high-quality protein crystals for structure determination, particularly in the case of membrane proteins, involves co-crystallization with a protein-specific antibody fragment. Here, we report the development of new recombinant single-chain antibody fragments (scFv) capable of binding a specific epitope that can be introduced into internal loops of client proteins. The previously crystallized hexa-histidine-specific 3D5 scFv antibody was modified in the complementary determining region and by random mutagenesis, in conjunction with phage display, to yield scFvs with new biochemical characteristics and binding specificity. Selected variants include those specific for the hexa-histidine peptide with increased expression, solubility (up to 16.6 mg/ml) and sub-micromolar affinity, and those with new specificity for the EE hexa-peptide (EYMPME) and nanomolar affinity. Complexes of one such chaperone with model proteins harboring either an internal or a terminal EE tag were isolated by gel filtration. The 3.1 Å resolution structure of this chaperone reveals a binding surface complementary to the EE peptide and a ∼52 Å channel in the crystal lattice. Notably, in spite of 85% sequence identity, and nearly identical crystallization conditions, the engineered scFv crystallizes in a different space group than the parent 3D5 scFv, and utilizes two new crystal contacts. These engineered scFvs represent a new class of chaperones that may eliminate the need for de novo identification of candidate chaperones from large antibody libraries.

Citing Articles

De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.

Entzminger K, Hyun J, Pantazes R, Patterson-Orazem A, Qerqez A, Frye Z Sci Rep. 2017; 7(1):10295.

PMID: 28860479 PMC: 5579192. DOI: 10.1038/s41598-017-10737-9.


Increased Fab thermoresistance via VH-targeted directed evolution.

Entzminger K, Johnson J, Hyun J, Lieberman R, Maynard J Protein Eng Des Sel. 2015; 28(10):365-77.

PMID: 26283664 PMC: 4596279. DOI: 10.1093/protein/gzv037.


Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization.

Johnson J, Entzminger K, Hyun J, Kalyoncu S, Heaner Jr D, Morales I Acta Crystallogr D Biol Crystallogr. 2015; 71(Pt 4):896-906.

PMID: 25849400 PMC: 4388267. DOI: 10.1107/S1399004715001856.


Effects of protein engineering and rational mutagenesis on crystal lattice of single chain antibody fragments.

Kalyoncu S, Hyun J, Pai J, Johnson J, Entzminger K, Jain A Proteins. 2014; 82(9):1884-95.

PMID: 24615866 PMC: 4142072. DOI: 10.1002/prot.24542.


Antibody-enabled small-molecule drug discovery.

Lawson A Nat Rev Drug Discov. 2012; 11(7):519-25.

PMID: 22743979 DOI: 10.1038/nrd3756.


References
1.
Sanner M . Python: a programming language for software integration and development. J Mol Graph Model. 2000; 17(1):57-61. View

2.
Baca M, Presta L, OConnor S, Wells J . Antibody humanization using monovalent phage display. J Biol Chem. 1997; 272(16):10678-84. DOI: 10.1074/jbc.272.16.10678. View

3.
Banatao D, Cascio D, Crowley C, Fleissner M, Tienson H, Yeates T . An approach to crystallizing proteins by synthetic symmetrization. Proc Natl Acad Sci U S A. 2006; 103(44):16230-5. PMC: 1637565. DOI: 10.1073/pnas.0607674103. View

4.
Derewenda Z . Rational protein crystallization by mutational surface engineering. Structure. 2004; 12(4):529-35. DOI: 10.1016/j.str.2004.03.008. View

5.
Sennhauser G, Grutter M . Chaperone-assisted crystallography with DARPins. Structure. 2008; 16(10):1443-53. DOI: 10.1016/j.str.2008.08.010. View